February 27, 2018 / 4:52 PM / 10 months ago

Roche says hemophilia drug Hemlibra wins EU approval

The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel, January 30, 2014. To match special report USA-FDA/CASES REUTERS/Ruben Sprich/File Photo

ZURICH (Reuters) - Swiss group Roche said on Tuesday the European Commission has approved its drug Hemlibra for people with hemophilia A who have developed resistance to standard treatments.

The approval was expected after a panel recommended it last month. The drug was already approved in the United States last year.

Hemlibra is among the new medicines that the Basel-based pharmaceuticals maker hopes will offset falling sales of its three biggest drugs, Rituxan, Avastin and Herceptin. Some analysts expect peak Hemlibra sales of more than $4 billion a year.

Reporting by Silke Koltrowitz, Editing by Michael Shields

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below